CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Khosla Ventures doubles down on Even Healthcare to challenge India’s hospital economics

From TechCrunch

By Jagmeet Singh

October 19, 2026

Khosla Ventures doubles down on Even Healthcare to challenge India’s hospital economics

Khosla Ventures doubles down on Even Healthcare to challenge India’s hospital economics

Even Healthcare has raised $50 million in a funding round led by Khosla Ventures, as the Indian startup seeks to change how hospitals in the world’s most populous country make money and how doctors are rewarded.

The all-equity Series B round also saw participation from Alpha Wave and valued it at $300 million, triple its valuation 18 months ago, according to Even. The latest funding brings Even’s total capital raised to more than $120 million.

Hospitals in India typically earn more when patients undergo additional tests, procedures, or longer stays, even when they may not need them. Even wants to change that by focusing on patient care rather than pushing unnecessary treatments that drive up medical bills.

That approach has continued to appeal to Khosla Ventures, which has invested in Even since its seed round in 2021. The Silicon Valley venture firm is doubling down as Even moves to build and operate hospitals of its own, giving it greater control over patient care and costs.

Vinod Khosla, founder of Khosla Ventures, said Even’s approach goes beyond fixing individual parts of a fragmented healthcare system by bringing financing, technology, and care delivery together. The goal, he said in a prepared statement, is to reward better health outcomes rather than greater use of healthcare services.

“The clinical and economic results so far give us conviction that this can become an important new model for healthcare in India and beyond,” Khosla said.

Initially, Even relied on partner hospitals to treat its members, but Mayank Banerjee, who founded the startup in 2021 with Matilde Giglio and Alessandro Ialongo, said in an interview that the startup began questioning that model after finding that patients had undergone tests or been recommended surgeries it considered unnecessary.

“We think patients are getting not only a bad experience, but insurers are getting a bad economic deal. And as a result, we decided to fix it by building our own hospitals,” Banerjee told TechCrunch.

Even has since opened two hospitals in Bengaluru, both of which reached operational profitability, excluding depreciation, within a year of opening, Banerjee stated. The startup plans to open five more hospitals in the southern Indian city over the next six months, funded by its latest round.

Banerjee told TechCrunch that Even leases hospital buildings on 20-year agreements and spends on fitting them out and buying medical equipment.

Unlike hospitals where doctors may have financial incentives to recommend more procedures, Even pays its doctors fixed salaries — not tying their compensation to the number of tests or surgeries they perform, though Banerjee said doctors can earn bonuses based on patient-reported clinical outcomes.

The same principle extends to hospital management, whose compensation is not linked to the number of procedures performed, Banerjee told TechCrunch. Managers, he said, receive salaries and company-wide incentives, while marketing teams focus on bringing in patients instead of the revenue those patients generate. Moreover, every employee, including doctors and other hospital staff, receives equity in Even. The idea is to give employees a stake in the startup’s long-term performance, not to reward them for generating more medical bills.

Most of Even’s revenue comes from patients paying for treatment, Banerjee said. The startup also generates revenue through its relationships with insurers. It is also working with insurer partners on a model that could compensate it for hospitalizations it helps prevent, not simply for providing more treatment.

Banerjee told TechCrunch that Even tracks how patients recover after treatment using established medical scoring systems. In the case of knee replacements, for instance, it uses the Oxford Knee Score to measure pain and mobility. The startup publishes results on its website, alongside figures from other healthcare systems for comparison.

Even says its hospitals have an unplanned readmission rate of less than 1%, compared with an industry benchmark of 8% to 15%. Furthermore, it claims patients spend 40% less time in the hospital and that its approach has saved insurers more than ₹500 million (about $5.27 million).

Jai Sajnani, a partner at Khosla Ventures, told TechCrunch that the early performance of Even’s hospitals was a key reason the firm led the round. “We look forward to helping the Even team put quality care within reach of every family in Bengaluru and across India,” he said.

Even is still losing money, though. The startup posted a net loss of ₹902 million (about $9.50 million) in fiscal 2025, nearly 25% more than the previous year, on revenue of ₹272 million (about $2.86 million), regulatory filings show.

In August, Even also laid off about 350 employees, according to Indian startup-news website Entrackr. Banerjee acknowledged the restructuring and called it a difficult decision. He said the affected employees received severance, extended health insurance, and accelerated equity vesting.

Even currently employs about 650 people, including around 300 doctors full-time. The startup has about 250,000 members and has recorded more than 750,000 patient interactions since its launch in 2021, including consultations, diagnostic tests, and surgeries, Banerjee said.

Banerjee told TechCrunch that Even could turn profitable within months if it stopped spending on expansion, but the startup is choosing to grow instead. He declined to say when the startup expects to become profitable.

“Right now, we’re investing in growth and serving more patients,” Banerjee said.

View original article on techcrunch.com

Most Recent

Disney agrees to hire the majority of Character.AI’s workforce

After chatbot startup Character.AI filed for bankruptcy earlier this week, many of its employees will have the opportunity to take jobs at Disney.

Oct 18, 2026

Elorian’s first AI model wants to reason with images, not just about them

According to Elorian's evaluations, Glimpse outperforms even GPT-6 Astra on scientific chart reasoning and short-form video captioning, with competitive results on other visual reasoning tasks.

Oct 16, 2026

Tressfecta wants to make hair braiding a less arduous task for hairstylists

Tressfecta builds products for textured hair. Its first project is a tool called Plait Pilot that helps braiders with the initial process of separating hair from packs before braiding begins.

Oct 16, 2026

Veritas expands its anti-counterfeit chip to jewelry, trophies, and fragrance bottles

Counterfeiters are getting better at replicating brands' marks and passing off dupes, known as "superfakes," as genuine items. A startup called Veritas wants to tackle the problem with its own chip that verifies goods.

Oct 16, 2026

Similar Posts

India’s HealthPlix raises $22M to accelerate growth and enhance healthcare delivery

HealthPlix, an Indian startup offering its in-house platform for doctors to help record patient data digitally, has raised $22 million in fresh investment to broaden its reach in the country and allow more doctors to utilize its software to offer improved care to their patients. In India, roughly 300,000 doctors practice medicine regularly. However, this […]

Mar 14, 2023

India’s HealthPlix raises $22M to accelerate growth and enhance healthcare delivery

HealthPlix, an Indian startup offering its in-house platform for doctors to help record patient data digitally, has raised $22 million in fresh investment to broaden its reach in the country and allow more doctors to utilize its software to offer improved care to their patients. In India, roughly 300,000 doctors practice medicine regularly. However, this […]

Mar 14, 2023

Accel eyes stake in India’s Truemeds at $330 million valuation

According to half a dozen sources, Accel, the global venture firm, is in advanced discussions to lead a funding round of $30 million to $40 million in Truemeds, an Indian online pharmacy that’s focused on providing customers with more affordable generic alternatives to costly branded medications. The talks are currently centered on a proposed valuation of about $330 million for the six-year-old, Mumbai-headquartered startup, per these same sources, who requested anonymity as the deliberations a

Oct 16, 2024

Sarvam becomes India’s newest AI unicorn with $234 million funding round led by HCLTech

Indian IT services company HCLTech is investing $150 million in the Bengaluru startup.

Jun 15, 2026